Sellas Vaccine Extends Survival in Blood Cancer Trial, Shares Surge

Sellas Life Sciences reported that its experimental vaccine, galinpepimut-S, extended survival in a late-stage trial for acute myeloid leukemia (AML) patients. The 126-patient study showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months for the control group. Sellas shares surged over 300% to $22.93, potentially adding $3.1B to its market value. The company plans to discuss an accelerated FDA approval strategy.

Original reporting
Published Nov 17, 2026, 7:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SLS
Bullish
high confidence
Mentioned
$SLS
Relevance
9/10
AlphAI data visualization · based on medscape.com
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

The trial’s reported risk reduction and median survival extension are material clinical endpoints, and management’s stated intent to pursue an accelerated FDA filing in 1H 2027 provides a near-term regulatory catalyst.

02

Market read

A clinically meaningful late-stage survival result plus a stated accelerated filing timeline is likely to drive sustained repricing and heightened volatility in SLS.

03

What to watch

Key risks include confirmatory trial requirements, manufacturing/scale-up for a personalized or immune-priming vaccine approach, and whether WT1-targeting efficacy holds across broader AML subgroups.

Relevance 9/10Novelty 9/10Timing: shares surged on the news; traders react immediately to trial readout and 2027 FDA filing plan

Background

Sellas Life Sciences is developing galinpepimut-S (GPS), an experimental vaccine targeting WT1-positive residual leukemia cells in AML patients in remission who cannot receive transplant.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

Sellas Life Sciences reports late-stage AML vaccine GPS cut death risk 41% and extends median survival to 24 months, driving a record one-day share surge.

Expected impact

Likely continued upside bias as traders price in expedited approval odds and a 2027 filing timeline, though volatility may persist on regulatory and confirmatory-data risk.

Evidence & confidence

The article discloses specific trial outcomes (risk reduction, median survival), a large same-day move (shares more than tripled), and a concrete plan to meet the FDA for accelerated filing in 1H 2027.

Market effects

Strengthens sentiment for oncology immunotherapy and vaccine platforms, potentially lifting peer interest in AML maintenance/relapse strategies.

Primarily US biotech sentiment, with global investors repricing risk for late-stage oncology programs.

May influence international expectations for AML treatment paradigms and accelerated approval pathways for immunotherapies.

Counterpoint

Even with a survival benefit, traders may discount durability, generalizability, and the chance that regulators require additional evidence beyond accelerated pathways.

Key entities

  • Sellas Life Sciences

    Developer of the GPS vaccine for AML, reporting late-stage trial survival benefit and planning FDA accelerated filing.

  • Galinpepimut-S (GPS)

    Experimental AML vaccine designed to train the immune system to attack WT1-carrying leukemia cells.

  • US FDA

    Regulatory body Sellas plans to meet to discuss an accelerated approval filing strategy.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?

Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.

$SLSMedAI 8/10

SELLAS shares jump 157% after company says its leukemia

SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.